| Display title | Chemistry:Etanercept |
| Default sort key | Etanercept |
| Page length (in bytes) | 26,038 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 248336 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>Rtexter1 |
| Date of page creation | 22:29, 24 April 2021 |
| Latest editor | imported>Rtexter1 |
| Date of latest edit | 22:29, 24 April 2021 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Etanercept, sold under the brand name Enbrel among others, is a biopharmaceutical that treats autoimmune diseases by interfering with tumor necrosis factor (TNF, a soluble inflammatory cytokine) by acting as a TNF inhibitor. It has U.S. F.D.A. approval to treat rheumatoid arthritis, juvenile idiopathic... |
